Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas

Blood

Volumn 120, Issue 11, 2012, Pages 2280-2289

  Vasmatzis, George ^a   Johnson, Sarah H ^a   Knudson, Ryan A ^a   Ketterling, Rhett P ^a   Braggio, Esteban ^b   Fonseca, Rafael ^c   Viswanatha, David S ^a   Law, Mark E ^a   Kip, N Sertac ^a   Özsan, Nazan ^d   Grebe, Stefan K ^a   Frederick, Lori A ^a   Eckloff, Bruce W ^a   Thompson, E Aubrey ^e   Kadin, Marshall E ^f   Milosevic, Dragana ^a   Porcher, Julie C ^a   Asmann, Yan W ^a   Smith, David I ^a   Kovtun, Irina V ^a,b   Ansell, Stephen M ^a   Dogan, Ahmet ^a   Feldman, Andrew L ^a   more..

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d EGE UNIVERSITY   (Turkey)

^e MAYO CLINIC   (United States)

^f ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; PROTEIN P53; PROTEIN P63;

ANKRD11 GENE; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CDKN2A GENE; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA LIBRARY; GENE DISRUPTION; GENE MUTATION; GENE REARRANGEMENT; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SURVIVAL RATE; TP53 GENE; TP63 GENE; TUMOR SUPPRESSOR GENE; WWOX GENE;

EID: 84866363110     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-419937     Document Type: Article

References (48)

1. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004; 15(10):1467-1475. (Pubitemid 39409735)
2. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 111(12):5496-5504.
3. Swerdlow S, Campo E, Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. In: Bosman F, Jaffe E, Lakhani S, Ohgaki H, eds. World Health Organization Classification of Tumours. 4 Ed. Lyon, France: International Agency for Research on Cancer; 2008.
4. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K. Peripheral T-cell lymphoma. Blood. 2011;117(25):6756-6767.
5. Gerber DE, Minna JD. ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell. 2010;18(6):548-551.
6. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23(3):574-580.
7. Feldman AL, Dogan A, Smith DI, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively-parallel genomic sequencing. Blood. 2011;117(3):915-919.
8. Wada DA, Law ME, Hsi ED, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596-605.
9. Graziano V, De Laurenzi V. Role of p63 in cancer development. Biochim Biophys Acta. 2011; 1816(1):57-66.
10. Feldman AL, Law M, Grogg KL, et al. Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. Am J Clin Pathol. 2008;130(2):178-185.
11. Feldman AL, Sun DX, Law ME, et al. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia. 2008;22(6):1139-1143. (Pubitemid 351833780)
12. Costa LJ, Feldman AL, Micallef IN, et al. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol. 2008;142(3):404-412. (Pubitemid 351962182)
13. Milosevic D, Lundquist P, Cradic K, et al. Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD. Clin Biochem. 2010;43(7-8): 700-704.
14. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005;576(1-2): 22-38. (Pubitemid 40982680)
15. Chang NS, Doherty J, Ensign A, Schultz L, Hsu LJ, Hong Q. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem. 2005; 280(52):43100-43108. (Pubitemid 43049276)
16. Neilsen PM, Cheney KM, Li CW, et al. Identification of ANKRD11 as a p53 coactivator. J Cell Sci. 2008;121(Pt 21):3541-3552.
17. Hedvat CV, Teruya-Feldstein J, Puig P, et al. Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol. 2005;13(3): 237-242. (Pubitemid 41209016)
18. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54(18):4855-4878. (Pubitemid 24289415)
19. Petit B, Leroy K, Kanavaros P, et al. Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. Hum Pathol. 2001;32(2):196-204. (Pubitemid 32193718)
20. Rassidakis GZ, Thomaides A, Wang S, et al. p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma. Leukemia. 2005;19(9):1663-1669. (Pubitemid 43090413)
21. Matsushima AY, Cesarman E, Chadburn A, Knowles DM. Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations. Am J Pathol. 1994; 144(3):573-584. (Pubitemid 24176763)
22. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med. 1998;4(7):839-843. (Pubitemid 28331028)
23. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest. 2007;117(5):1370-1380. (Pubitemid 46718425)
24. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell. 2006; 9(1):45-56. (Pubitemid 43069510)
25. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63(21):7113-7121. (Pubitemid 37413448)
26. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res. 2006; 66(19):9362-9368. (Pubitemid 44623630)
27. Vilgelm A, El-Rifai W, Zaika A. Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat. 2008;11(4-5):152-163.
28. Su X, Chakravarti D, Cho MS, et al. TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature. 2010;467(7318): 986-990.
29. Guo X, Keyes WM, Papazoglu C, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol. 2009;11(12):1451-1457.
30. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2(3):305-316. (Pubitemid 128379271)
31. Chiang CT, Chu WK, Chow SE, Chen JK. Overexpression of delta Np63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J Cell Physiol. 2009;219(1):117-122.
32. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000; 1(3):199-207.
33. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene. 2000;19(30):3439- 3444. (Pubitemid 30479339)
34. Mundt HM, Stremmel W, Melino G, Krammer PH, Schilling T, Muller M. Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways. Biochem Biophys Res Commun. 2010;396(2):335-341.
35. Trink B, Osada M, Ratovitski E, Sidransky D. p63 transcriptional regulation of epithelial integrity and cancer. Cell Cycle. 2007;6(3):240-245.
36. Fomenkov A, Huang YP, Topaloglu O, et al. P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem. 2003;278(26):23906-23914. (Pubitemid 36830218)
37. Amoresano A, Di Costanzo A, Leo G, et al. Identification of DeltaNp63alpha protein interactions by mass spectrometry. J Proteome Res. 2010;9(4): 2042-2048.
38. Packard A, Schnittke N, Romano RA, Sinha S, Schwob JE. DeltaNp63 regulates stem cell dynamics in the mammalian olfactory epithelium. J Neurosci. 2011;31(24):8748-8759.
39. Nekulova M, Holcakova J, Coates P, Vojtesek B. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011;16(2):296-327.
40. Cheung KJ, Horsman DE, Gascoyne RD. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target. Br J Haematol. 2009;146(3):257-269.
41. Scott DW, Mungall KL, Ben-Neriah S, et al. TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. Blood. 2012; 119(21):4949-4952.
42. Pinyol M, Cobo F, Bea S, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 1998;91(8):2977-2984. (Pubitemid 28227549)
43. Laharanne E, Chevret E, Idrissi Y, et al. CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol. 2010; 23(4):547-558.
44. Powell JA, Gardner AE, Bais AJ, et al. Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics. 2002; 80(3):303-310. (Pubitemid 34985020)
45. Noll JE, Jeffery J, Al-Ejeh F, et al. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene. 2012;31(23):2836-2848.
46. Jenner MW, Leone PE, Walker BA, et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007;110(9):3291-3300. (Pubitemid 350106322)
47. Sanchez-Schmidt JM, Salgado R, Servitje O, et al. Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach. J Invest Dermatol. 2011;131(1):269-271.
48. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010;70(20): 7970-7980.